Stadigh Anni E, Puska Päivi M, Kivelä Tero T
Glaucoma Service, Department of Ophthalmology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland; Ocular Oncology Service, Department of Ophthalmology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Glaucoma Service, Department of Ophthalmology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Ophthalmol Glaucoma. 2023 Jan-Feb;6(1):29-41. doi: 10.1016/j.ogla.2022.08.002. Epub 2022 Aug 12.
To estimate incidence of and analyze risk factors for developing secondary glaucoma in eyes with uveal melanoma before and after diagnosis.
A cross-sectional, population-based cohort study.
Seven hundred eighty-one patients (median age, 64 years; range, 14-93) consecutively diagnosed with uveal melanoma from 1997 to 2012 in a national ocular oncology service, 708 (91%) of whom received ruthenium (50%) or iodine (50%) brachytherapy.
Patient, tumor, treatment, and follow-up data were collected prospectively. Frequency and associations of melanoma-related glaucoma at tumor diagnosis were assessed. Incidence of developing secondary glaucoma after diagnosis was estimated by Kaplan-Meier analysis. Independent risk factors were modeled using Cox regression.
Melanoma-related glaucoma and related risk factors.
Forty-five patients (5.8%; 95% confidence interval [CI], 4.2-7.6) had tumor-related secondary glaucoma at diagnosis, 34 (76%) from a narrow-to-closed angle (25 had direct angle invasion) and 10 (22%) from anterior neovascularization. Synchronous metastases were common in patients with initial secondary glaucoma (11% vs. 1.2% with incident glaucoma, P = 0.005). Patients with secondary glaucoma were often male (58% vs. 48% without glaucoma; P = 0.010) and had larger tumors (median thickness, 9.1 vs. 4.0 mm; P < 0.001) involving the ciliary body (43% vs. 21%; P < 0.001) with retinal detachment (53% vs. 30%; P < 0.001). One hundred and sixty-eight patients 165 of which were treated with brachytherapy developed incident tumor- or treatment-related secondary glaucoma a median of 1.7 years (range, 0.1-13.6) after tumor diagnosis. Cumulative proportion of developing secondary glaucoma was 23% (95% CI, 20-27) at 5 years. The most common mechanism was neovascularization in 119 patients (71%; 95% CI, 63-78). By multivariable regression, initial retinal detachment 3 to 4 quadrants (hazard ratio [HR], 2.18; P < 0.001), initial intraocular pressure 17 mmHg or higher (HR, 1.64; P = 0.01), and tumor thickness predicted incident secondary glaucoma.
Secondary glaucoma at initial uveal melanoma diagnosis predicts high risk of synchronous metastases. Although anterior neovascularization is the most common mechanism for secondary glaucoma after diagnosis, other mechanisms such as angle narrowing and anterior chamber hemorrhage are not infrequent. Initial retinal detachment and intraocular pressure with tumor thickness could inform interim assessments of intraocular pressure and neovascularization.
评估葡萄膜黑色素瘤患者在诊断前后发生继发性青光眼的发生率,并分析相关危险因素。
一项基于人群的横断面队列研究。
1997年至2012年在一家国家眼科肿瘤服务机构连续诊断为葡萄膜黑色素瘤的781例患者(中位年龄64岁;范围14 - 93岁),其中708例(91%)接受了钌(50%)或碘(50%)近距离放射治疗。
前瞻性收集患者、肿瘤、治疗及随访数据。评估肿瘤诊断时黑色素瘤相关性青光眼的频率及相关因素。采用Kaplan-Meier分析估计诊断后发生继发性青光眼的发生率。使用Cox回归对独立危险因素进行建模。
黑色素瘤相关性青光眼及相关危险因素。
45例患者(5.8%;95%置信区间[CI],4.2 - 7.6)在诊断时有肿瘤相关性继发性青光眼,34例(76%)为窄角至闭角型(25例有直接房角侵犯),10例(22%)为前部新生血管形成。初始继发性青光眼患者中同步转移很常见(11%对比有青光眼发病的患者为1.2%,P = 0.005)。继发性青光眼患者常为男性(58%对比无青光眼患者为48%;P = 0.010),肿瘤较大(中位厚度9.1对比4.0 mm;P < 0.001),累及睫状体(43%对比21%;P < 0.001)且伴有视网膜脱离(53%对比30%;P < 0.001)。168例患者(其中165例接受近距离放射治疗)在肿瘤诊断后中位1.7年(范围0.1 - 13.6年)发生了与肿瘤或治疗相关的继发性青光眼。5年时发生继发性青光眼的累积比例为23%(95% CI,20 - 27)。最常见的机制是119例患者(占71%;95% CI,63 - 78)的新生血管形成。通过多变量回归分析,初始3至4个象限的视网膜脱离(风险比[HR],2.18;P < 0.001)、初始眼压17 mmHg或更高(HR,1.64;P = 0.01)以及肿瘤厚度可预测继发性青光眼的发病。
葡萄膜黑色素瘤初始诊断时的继发性青光眼预示着同步转移的高风险。虽然前部新生血管形成是诊断后继发性青光眼最常见的机制,但其他机制如房角变窄和前房出血也并不少见。初始视网膜脱离、眼压及肿瘤厚度可用于眼压和新生血管形成的中期评估。